Traws Pharma is a clinical stage company that aims to address unmet medical needs in respiratory viral diseases and cancer. It develops novel product candidates leveraging expertise in small molecule chemistry, artificial intelligence, machine learning, and rational drug design.

Traws Pharma

Amgen Bangladesh is a subsidiary of Amgen Inc., one of the world's leading biotechnology companies. The company is dedicated to discovering, developing, manufacturing, and delivering innovative human therapeutics. It focuses on areas of high unmet medical need, leveraging expertise in biology, chemical engineering, and a variety of other scientific disciplines to develop medicines that can help millions of patients around the world.

George Rathmann

Amgen Bangladesh

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Metric
Company Name	Traws Pharma	Amgen Bangladesh	Gilead Sciences, Inc.
Symbol			GILD
MSH ID	COM:TRAWSPHARMA	COM:AMGENBD	COM:GILEAD
Market	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology	Drug Manufacturers - General
Country	US		US
Stage
Employee Count		10.00K	18K
Website	trawspharma.com	amgenbd.com	gilead.com
LinkedIn			gilead-sciences
Founders

Metric
Market Cap			85.65B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue			27.12B
Revenue (LTM)
Revenue (NTM)
Gross Profit			27.12B
EBITDA			7.61B
Operating Income			7.61B
Net Income			5.67B
EPS			4.54
Diluted EPS			4.50
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin			0.78
Operating Profit Margin			0.36
EBITDA Margin			0.28
Net Profit Margin			0.21
Return on Equity			0.26
Return on Assets			0.09
Return on Capital Employed			0.24

TRAW

COM:TRAWSPHARMA

Traws Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio			16.30
P/B Ratio			4.31
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio			3.91
EV Multiple			23.26

Metric
Days Sales Outstanding			63.83
Days Payables Outstanding			36.85
Days Inventory Outstanding			205.86
Operating Cycle			268.59
Cash Conversion Cycle			262.69
Asset Turnover			0.52

Metric
Operating Cash Flow			8.01B
Free Cash Flow			7.42B
Cash Flow to Debt			0.34
Operating Cash Flow/Sales			0.31
Free Cash Flow Yield			0.08

Metric
Cash & Equivalents			6.08B
Accounts Receivable			157M
Inventory			3.37B
Goodwill			8.31B
Debt to Capitalization			0.60
Debt to Assets			0.42
Current Ratio			1.34
Quick Ratio			1.08

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue			0.02
R&D to Revenue			0.21
SG&A to Revenue